

KISUNLA (donanemab-azbt) ORDER FORM P: 240.200.4464 F: 240.892.3005

PATIENT INFO	PRMATION: Fax cor	npleted form, insurance inf	formation, and clinical c	locumentation to 240.892.30	05
Patient Name:		DOB:	Phone:		
Patient Status:	New to Therapy	Continuing Therapy	Next Treatment Da	te:	_
MEDICAL INF	ORMATION				
Diagnosis:	er's Disease with Earl gnitive Impairment (Ider for clinical registry DER mg IV for 3 infusions should be performe	y Onset (ICD-10: G30.0)	*MEDICARE REQUIRED wed by 1400 mg IV e 2 nd , 3 rd , 4 th , and 7 th in	* every 4 weeks	
☐ Patient enrol	led in the CMS Natio	nal Patient Registry (Medi	care and Medicare Adv	• • •	AL
		Date of registry			
☐ Confirmed pri☐ MRI of the bri☐ Cognitive ass☐ MM	resence of amyloid parain (within 1 year) — sessment scores (list a SE: Score	al patient registry confirmathology. Attach results: Arattach results all available, attach results) Date of assessment Date of assessment	nyloid PET scan OR +CS	F (cerebrospinal fluid)	
Please provide the complete insurance team will notify yo	e patient's demograph e verification and subr u if any additional info	ic information, insurance in nit all required documentation	formation, medication li on for approval to the pa review financial respons	st, and clinical notes. Active In tient's insurance company for ibility with the patient and assi referral.	eligibility. Our
PROVIDER IN	FORMATION				
Provider Name:		Signatur	e:	Date:	
Provider NPI:		Phone:		Fax:	
Contact Person:					